KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Travere Therapeutics (TVTX) Income from Continuing Operations (2016 - 2025)

Travere Therapeutics' Income from Continuing Operations history spans 15 years, with the latest figure at 21986000.0 for Q4 2025.

  • For Q4 2025, Income from Continuing Operations rose 63.52% year-over-year to 21986000.0; the TTM value through Dec 2025 reached 50261000.0, up 84.32%, while the annual FY2025 figure was 50261000.0, 84.32% up from the prior year.
  • Income from Continuing Operations reached 21986000.0 in Q4 2025 per TVTX's latest filing, down from 25706000.0 in the prior quarter.
  • In the past five years, Income from Continuing Operations ranged from a high of 25706000.0 in Q3 2025 to a low of 135958000.0 in Q1 2024.
  • Average Income from Continuing Operations over 5 years is 64799200.0, with a median of 74837500.0 recorded in 2022.
  • Peak YoY movement for Income from Continuing Operations: crashed 6574.4% in 2021, then surged 146.95% in 2025.
  • A 5-year view of Income from Continuing Operations shows it stood at 88774000.0 in 2021, then grew by 3.53% to 85636000.0 in 2022, then dropped by 3.46% to 88596000.0 in 2023, then skyrocketed by 31.97% to 60268000.0 in 2024, then skyrocketed by 63.52% to 21986000.0 in 2025.
  • Per Business Quant, the three most recent readings for TVTX's Income from Continuing Operations are 21986000.0 (Q4 2025), 25706000.0 (Q3 2025), and 12755000.0 (Q2 2025).